

Ref: MHL/Sec&Legal/2021-22/35

Date: August 6, 2021

To,
Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

Head, Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Scrip Code: 542650

Scrip Symbol: METROPOLIS

Sub: Intimation of Press Release

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a Press Release as mentioned below:

‘Metropolis Healthcare Limited records strong growth in Q1FY22 Revenue, EBITDA & PAT.’

You are requested to take the above information on record.

Thanking You,

Yours Faithfully

For **Metropolis Healthcare Limited**

Ameera Sushil Shah
Managing Director
DIN: 00208095
Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 **Tel No.:** 8422 801 801 **Email:** support@metropolisindia.com
Website: www.metropolisindia.com
Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis Healthcare Ltd records strong growth in Q1FY22 Revenue, EBITDA & PAT

Reported PAT at Rs. 75 Crores

- Recorded highest ever quarterly patient visits at 3.5 Mn & number of tests at 6.5 Mn
- Patient visits grew by 11% and number of tests grew by 1% on QoQ basis
- Revenue from home visits business increased by 19% QoQ to Rs. 37 Crores in Q1FY22

Mumbai, August 06, 2021: Metropolis Healthcare Ltd. (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its unaudited consolidated financial results today for the first quarter (Q1FY22).

Financial Highlights

INR. 327 cr

Revenue
+12% QoQ

59%

Revenue Share of B2C in Focus
Cities (Non-Covid)

INR. 75 cr

Reported PAT
+22% QoQ

We take immense pleasure in announcing that we have successfully continued from our last quarter and have delivered our highest ever quarterly revenue supplemented strongly, by both our COVID and non-COVID revenues. Metropolis Healthcare Ltd. continues to work and support our government and healthcare fraternity in the fight against COVID-19, even as we march on in our tireless efforts to grow exponentially as a brand, provide incremental value to our shareholders, and the best in quality to our customers. Digital transformation remains focal for us, in our relentless pursuit of world-class customer experience. We always have, and will continue to, prioritize safety, quality, and hygiene.

While the pandemic still lurks over our shoulder, we have seen a strong acceptance to brand Metropolis which is visible in our growth across the board.

Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.

ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

RECENT AWARDS AND ACCOLADES

Our MD, Ms. Ameera Shah won the prestigious Entrepreneur of the Year Award by EY in Lifesciences and Healthcare category

Metropolis Healthcare won the Leading Diagnostic Chain of the Year award at the Elets Diagnostics Leadership Summit, 2021

Metropolis Healthcare Ltd won the 2020 Indian Diagnostic Services Industry Company of the Year Award organised by Frost & Sullivan.

Metropolis Healthcare won the award for Outstanding Logistics Unit during Pandemic award in the Healthcare Category organised by Supply Chain and Logistics Excellence (SCALE) Awards

Metropolis won five different awards for its CSR Projects from different reputed CSR platforms.

Our CFO, Mr. Rakesh Agarwal was awarded at the 11th Annual CFO Awards for his exceptional contribution to the world of finance.

Our MD, Ms. Ameera Shah has been listed in Asia's Power Businesswomen 2020 by Forbes Asia

Our MD, Ms. Ameera Shah has been listed in Asia's Power Businesswomen 2020 by Forbes Asia

Ms. Ameera Shah has been bestowed with Mumbai Ratna Award in recognition of her remarkable contributions to the community during the COVID 19 pandemic

In INR Crs.	Q1FY22	Q4FY21
Revenue from Operations	326.8	291.7
EBIDTA before CSR & ESOP	105.6	103.5
Reported Profit After Tax	74.9	61.3
Reported PAT Margin (%)	22.9%	21.0%

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 20 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports.

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Ms. Aishwarya Jayaram – Corporate Communications

aishwarya.jayaram@metropolisindia.com

www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Shrenik Shah

shogun.jain@sgapl.net / shrenik.shah@sgapl.net